Bausch Health Companies Inc.

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

Bausch Health Companies stock surged nearly 40% in July 2026, driven by a regulatory win in Canada for its Prokedi schizophrenia drug and a strong Q2 earnings beat. The company reported $2.85 billion in revenue (13% YoY growth) and adjusted net income of $476 million ($1.26 per share), exceeding analyst expectations. Management raised full-year 2026 guidance for both revenue and adjusted EBITDA, citing strength across its diversified pharmaceutical portfolio.